Healthcare coverage affects survival of EGFR-mutant Thai lung cancer patients

Despite significant benefits of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment in patients with -mutated NSCLC, access remains limited in Thailand and elsewhere. Retrospective analysis of patients with locally advanced/recurrent NSCLC and known mutation ( m) status t...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in oncology 2023-02, Vol.13, p.1047644-1047644
Main Authors: Khiewngam, Khantong, Oranratnachai, Songporn, Kamprerasart, Kaettipong, Kunakorntham, Patratorn, Sanvarinda, Pimtip, Trachu, Narumol, Pimsa, Pongput, Wiwitkeyoonwong, Jirapath, Thamrongjirapat, Thanaporn, Dejthevaporn, Thitiya, Sirachainan, Ekaphop, Reungwetwattana, Thanyanan
Format: Article
Language:English
Subjects:
drug reimbursement
EGFR-TKI
healthcare coverage
non-small cell lung cancer
Oncology
targeted therapy
Thailand
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Despite significant benefits of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment in patients with -mutated NSCLC, access remains limited in Thailand and elsewhere. Retrospective analysis of patients with locally advanced/recurrent NSCLC and known mutation ( m) status treated at Ramathibodi Hospital (2012-2017). Prognostic factors for overall survival (OS), including treatment type and healthcare coverage, were analyzed using Cox regression. Of 750 patients, 56.3% were m-positive. After first-line therapy (n=646), 29.4% received no subsequent (second-line) treatment. EGFR-TKI-treated m-positive patients survived significantly longer than m-negative patients without EGFR-TKIs (median OS [mOS] 36.4 vs. 11.9 months; hazard ratio HR=0.38 [95%CI 0.32-0.46],
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2023.1047644